{"classes":[{"categories":[{"measurements":[{"comment":"The 95% upper confidence limit was not reached.","groupId":"OG000","lowerLimit":"25.2","upperLimit":"NA","value":"38.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression. If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death.\n\nProgressive disease is defined as having one of the following:\n\n* The appearance of any new lesion more than 1.5 cm in any axis during or at the end of therapy, even if other lesions are decreasing in size.\n* At least a 50% increase from nadir in the sum of the product of the dimension (SPD) of any previously involved nodes.\n* At least a 50% increase in the longest diameter of any single previously identified node more than 1 cm in its short axis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:\n\n375 mg/m\\^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m\\^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22.","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 1 year from registration.","title":"Progression-free Survival Time","type":"SECONDARY","unitOfMeasure":"months"}